| Alec Pramhus, MD | |
|
525 S Watson Rd Ste 200, Buckeye, AZ 85326-3451 | |
| (602) 726-8750 | |
| (623) 474-5811 |
| Full Name | Alec Pramhus |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 525 S Watson Rd Ste 200, Buckeye, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225481740 | NPI | - | NPPES |
| 58323 | Other | AZ | FAMILY MEDICINE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R-10652 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vhs Outpatient Clinics Inc | 4486566726 | 157 |
News Archive
An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.
Snoring, older age and obesity may increase a pregnant woman's risk for sleep apnea-or interrupted breathing during sleep-according to researchers funded by the National Institutes of Health.
A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.
› Verified 5 days ago
| Entity Name | Vhs Outpatient Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912979964 PECOS PAC ID: 4486566726 Enrollment ID: O20031104000523 |
News Archive
An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.
Snoring, older age and obesity may increase a pregnant woman's risk for sleep apnea-or interrupted breathing during sleep-according to researchers funded by the National Institutes of Health.
A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alec Pramhus, MD 525 S Watson Rd Ste 200, Buckeye, AZ 85326-3451 Ph: (602) 726-8750 | Alec Pramhus, MD 525 S Watson Rd Ste 200, Buckeye, AZ 85326-3451 Ph: (602) 726-8750 |
News Archive
An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.
Snoring, older age and obesity may increase a pregnant woman's risk for sleep apnea-or interrupted breathing during sleep-according to researchers funded by the National Institutes of Health.
A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.
› Verified 5 days ago
John F Konings, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 306 E Monroe Ave, Buckeye, AZ 85326 Phone: 623-836-4814 Fax: 623-386-4593 | |
Megan Blackburn, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 S Watson Rd Ste 200, Buckeye, AZ 85326 Phone: 602-726-8750 Fax: 623-925-0745 | |
Mr. Richard A Ayiyi Jr., FNP-C Family Medicine Medicare: Medicare Enrolled Practice Location: 23556 W Huntington Dr, Buckeye, AZ 85326 Phone: 480-694-0018 | |
Sultan Mohammad, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 S Watson Rd, Ste 104, Buckeye, AZ 85326 Phone: 623-251-3201 Fax: 623-251-3205 | |
Uzma Jafri, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 23374 W Yuma Rd, Suite 102, Buckeye, AZ 85326 Phone: 832-768-5370 | |
Matthew Duke, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1209 N Miller Rd, Buckeye, AZ 85326 Phone: 623-386-5785 Fax: 623-386-6673 |